Home » POZEN MOVES FORWARD WITH PN 200 TRIALS
POZEN MOVES FORWARD WITH PN 200 TRIALS
Pozen has completed a special protocol assessment (SPA) and reached agreement with the FDA on the design of its pivotal trials for PN 200. PN 200 is a product candidate for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric ulcers.
PN 200 is a combination of an acid inhibitor with a NSAID in a single tablet. The product is intended to manage pain and inflammation with fewer gastrointestinal side effects and less gastric damage, including ulcers, compared to an NSAID taken alone.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May